RLF — RELIEF THERAPEUTICS Holding SA Share Price
Last trade - 00:00- CH₣29.53m
- CH₣16.60m
- CH₣8.42m
- 28
- 26
- 27
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.81 | ||
| Price to Tang. Book | 5.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.51 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.78% | ||
| Return on Equity | -38.52% | ||
| Operating Margin | -227.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | n/a | 3.32 | 6.08 | 6.03 | 8.42 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
Directors
- Raghuram Selvaraju CHM (40)
- Jack Weinstein CFO (65)
- Taneli Jouhikainen COO (54)
- Gilles Della Corte OTH
- Christiaan Stijnen OTH (58)
- Paolo Galfetti DRC
- Patrice Jean DRC
- Thomas Plitz DRC (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 13th, 2017
- Public Since
- September 19th, 2011
- No. of Employees
- 36
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 12,540,439
- Address
- Avenue de Secheron 15, GENEVE, 1202
- Web
- https://relieftherapeutics.com/
- Phone
- +41 447235959
- Contact
- Jeremy Meinen
- Auditors
- Forvis Mazars
Latest News for RLF
Upcoming Events for RLF
Relief Therapeutics Holding SA Annual Shareholders Meeting
Half Year 2025 Relief Therapeutics Holding SA Earnings Release
Similar to RLF
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
Basilea Pharmaceutica AG Allschwil
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
FAQ
As of Today at 22:55 UTC, shares in RELIEF THERAPEUTICS Holding SA are trading at CH₣2.36. This share price information is delayed by 15 minutes.
Shares in RELIEF THERAPEUTICS Holding SA last closed at CH₣2.36 and the price had moved by +99.2% over the past 365 days. In terms of relative price strength the RELIEF THERAPEUTICS Holding SA share price has outperformed the FTSE Global All Cap Index by +94.21% over the past year.
There is no consensus recommendation for this security.
Find out moreRELIEF THERAPEUTICS Holding SA does not currently pay a dividend.
RELIEF THERAPEUTICS Holding SA does not currently pay a dividend.
RELIEF THERAPEUTICS Holding SA does not currently pay a dividend.
To buy shares in RELIEF THERAPEUTICS Holding SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣2.36, shares in RELIEF THERAPEUTICS Holding SA had a market capitalisation of CH₣29.53m.
Here are the trading details for RELIEF THERAPEUTICS Holding SA:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: RLF
Based on an overall assessment of its quality, value and momentum RELIEF THERAPEUTICS Holding SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RELIEF THERAPEUTICS Holding SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -60.9%.
As of the last closing price of CH₣2.36, shares in RELIEF THERAPEUTICS Holding SA were trading -26.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RELIEF THERAPEUTICS Holding SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣2.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
RELIEF THERAPEUTICS Holding SA's management team is headed by:
- Raghuram Selvaraju - CHM
- Jack Weinstein - CFO
- Taneli Jouhikainen - COO
- Gilles Della Corte - OTH
- Christiaan Stijnen - OTH
- Paolo Galfetti - DRC
- Patrice Jean - DRC
- Thomas Plitz - DRC